KRMDMEDIUM SIGNALFINANCIAL10-K

KRMD showed meaningful operational improvement with 22% revenue growth and substantially reduced losses despite removing language about needing additional funding.

The company appears to be executing a successful turnaround, with revenue growth driving improved profitability metrics and management confident enough to remove previous concerns about capital needs. The shift from acquisition-focused language to operational execution suggests a more disciplined strategic approach, though new risks around distributor concentration and talent retention warrant monitoring.

Comparing 2026-03-12 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

KRMD delivered solid revenue growth of 22% to $41.1M with corresponding gross profit expansion, while meaningfully reducing both operating losses and net losses through disciplined cost management including lower R&D spending. The company maintained a healthy balance sheet with modest inventory build-up and controlled liability growth, while significantly reducing share buyback activity and increasing capital expenditures to support growth initiatives.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-88.4%
$24K$3K

Buyback activity reduced 88.4% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
+66.8%
$122K$203K

Capital expenditure jumped 66.8% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
+56.5%
-$6.1M-$2.6M

Net income grew 56.5% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+53.9%
-$6.4M-$3.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
-44.7%
$3K$2K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Inventory
Balance Sheet
+31.2%
$2.8M$3.7M

Inventory surged 31.2% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Revenue
P&L
+22.2%
$33.6M$41.1M

Revenue growing 22.2% — solid top-line momentum, watch margins for quality of growth.

Gross Profit
P&L
+20%
$21.3M$25.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

R&D Expense
P&L
-16.6%
$5.3M$4.4M

R&D spending cut 16.6% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
+13.8%
$7.2M$8.2M

Current liabilities rose 13.8% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-12
ADDED
As of March 12, 2026, 46,370,432 shares of common stock, $0.01 par value per share, were outstanding, which excludes 3,438,526 shares of Treasury Stock.
The size of the markets for our products and any future products may be smaller than we estimate and may decline.
We sell a majority of our products through a limited number of distributors on whom we depend, and our financial results depend on their purchasing patterns, as well as with end-user demand.
We need to attract and retain key employees to be competitive.
could impact our operations or the operations of our suppliers and vendors, and the ability to retain talented personnel.
+7 more — sign up free →
REMOVED
As of March 12, 2025, 45,957,115 shares of common stock, $0.01 par value per share, were outstanding, which excludes 3,438,526 shares of Treasury Stock.
We may need additional funding in the future, and if we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate our product development, commercial efforts, or sales efforts.
We may experience difficulties resulting from our relatively new management structure and executive team.
A downturn in global economic conditions could adversely affect our operations.
Our distribution network and other operations outside the U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →